William Blair Investment Management LLC Buys New Holdings in Repligen Corporation $RGEN

Key Points

• William Blair Investment Management bought 788,571 Repligen shares worth approximately $107.6 million, giving it a 1.40% stake. Institutional investors collectively own 97.64% of the company.
• Analysts maintain a positive outlook, with a consensus “Buy” rating and an average price target of $166.43; Benchmark upgraded the stock to “Buy” with a $185 target.
• Repligen exceeded quarterly expectations, reporting $0.54 in EPS versus the $0.45 estimate and $204.13 million in revenue, up 11.9% year over year. Shares opened at $181.13, near the company’s 52-week high of $188.73.

William Blair Investment Management LLC purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 788,571 shares of the biotechnology company's stock, valued at approximately $107,593,000. William Blair Investment Management LLC owned about 1.40% of Repligen at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Measured Wealth Private Client Group LLC bought a new stake in Repligen in the third quarter valued at approximately $29,000. Bayforest Capital Ltd bought a new position in shares of Repligen in the fourth quarter worth approximately $32,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen in the fourth quarter worth $33,000. Los Angeles Capital Management LLC purchased a new position in shares of Repligen in the fourth quarter worth $36,000. Finally, Farther Finance Advisors LLC raised its holdings in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock valued at $55,000 after buying an additional 128 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RGEN has been the subject of several analyst reports. Benchmark raised shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. Barclays boosted their price objective on shares of Repligen from $145.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday, May 6th. Wells Fargo & Company increased their target price on shares of Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th. Jefferies Financial Group reissued a "hold" rating and issued a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. Finally, JPMorgan Chase & Co. raised their target price on Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $166.43.

Repligen Stock Performance

Shares of RGEN opened at $181.13 on Friday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The stock has a market cap of $10.22 billion, a P/E ratio of 248.12, a P/E/G ratio of 3.29 and a beta of 1.03. The business's 50 day moving average price is $147.16 and its 200-day moving average price is $131.88. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $188.73.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the firm's stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is owned by insiders.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source